Method of solubilizing and encapsulating itraconazole

Description

FIELD OF THE INVENTION

The present invention relates to the preparation of solutions containing imidazole derivatives and to the use of those solutions in the preparation of microspheres. The imidazole derivative containing microspheres are effective in treating fungal infections, particularly in mammals. The microspheres facilitate the oral administration of relatively large amounts of the imidazole derivative, with increased bioavailability.

BACKGROUND OF THE INVENTION

Many present systems for delivering active agents to targets are severely limited by biological, chemical, and physical barriers, which are imposed by the environment through which delivery occurs, the environment of the target itself, or the target itself. Delivery is also limited, in many instances, by the chemical nature of the active agent. For example, oral delivery is generally ineffective with active agents that are poorly water-soluble.

The imidazole derivative family of compounds is particularly effective against a broad range of fungal infections such as those caused by

Trichophyton rubrum, Tricophyton mentagrophytes, Epidermophyton floccsum,

and

Candida albicans,

but these compounds are either partially water soluble or insoluble in water. For example, the solubility of itraconazole in water is less than 0.00001 g/ml.

Partially because imidazole derivatives are typically insoluble in water, they are difficult to administer orally. Consequently although imidazole derivatives are frequently prescribed for the treatment of fungal infections, they have been available only in topical preparations or in oral formulations with limited bioavailability.

In recent years, fungal infections, such as those caused by

Candida albicans

in particular have become more prevalent and intractable due to their appearance in immunocompromised patients, such as those infected with Human Immunodeficiency Virus (HIV) or those suffering from Acquired Immunodeficiency Syndrome (AIDS).

For example, U.S. Pat. No. 3,717,655 discloses imidazole derivatives which have antifungal and antibacterial activity. These compounds are almost insoluble in aqueous solutions such as water and are very poorly soluble in polar solvents such as ethanol.

Das et al., U.S. Pat. No. 4,912,124, disclose a solvent system for imidazole derivatives that include mixtures of a polar solvent, a polyhydric alcohol that acts as a solubilizing agent, a nonionic or amphoteric surfactant, and a cosmetic humectant. Solutions containing at least 1 percent by weight of the imidazole derivatives can be formulated using this solvent system. However, these formulations are suitable for external topical use only.

Accordingly, there is a need for orally deliverable forms of imidazole derivative antifungal agents.

SUMMARY OF THE INVENTION

The present invention provides solutions comprising:

(a) at least about 2.5 parts by weight, based upon 100 parts by weight of solution, of a solute having the formula

wherein R, R

1

, and R

2

are independently hydrogen or lower alkyl;

R

3

is hydrogen, methyl or ethyl;

R

4

is hydrogen or methyl

Ar is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or halothienyl;

Ar

1

is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or cyanophenyl; and

n is 1 or 2; and

(b) a solubilizing effective amount of a solvent comprising at least one volatile organic acid solvent.

Imidazole derivative microspheres are also provided. These microspheres comprise:

(a) an imidazole derivative active agent having the formula

wherein

R, R

1

, and R

2

are independently hydrogen or lower alkyl;

R

3

is hydrogen, methyl or ethyl;

R

4

is hydrogen or methyl

Ar is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl,. lower alkoxyphenyl, or halothienyl;

Ar

1

is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or cyanophenyl; and

n is 1 or 2;

(b) an active agent and carrier solubilizing effective amount of a solvent comprising an aqueous solution of at least one volatile organic solvent; and wherein the volume:volume ratio of acid to water in said carrier solution is at least about 3:7, and

(c) microsphere forming a carrier selected from the group consisting of

(i) a proteinoid;

(ii) an acylated amino acid or poly amino acid or a salt thereof;

(iii) an sulfonated amino acid or poly amino acid or a salt thereof;

(iv) a protein or a salt thereof;

(v) an enteric coating material, or

(vi) any combination thereof; and

(B) decreasing said ratio to less than about 3:7, to yield said microspheres. Alternatively, the active agent and the carrier can be solubilized in separate solutions. The separate solutions can be nebulized together and the acid to water ratio then decreased as above.

Methods for the oral administration of imidazole derivatives are also contemplated wherein the microsphere compositions above are orally administered to an animal in need of this treatment.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A

is a scanning electron micrograph (SEM) taken at a magnification of 2,000× of microspheres containing itraconazole prepared according to the present invention.

FIG. 1B

is a SEM taken at a magnification of 15,000× of microspheres containing itraconazole prepared according to the present invention.

FIG. 1C

is a SEM taken a magnification of 20,000× of microspheres containing itraconazole prepared according to the present invention.

FIG. 1D

is a SEM taken at a magnification of 20,000× of microspheres containing itraconazole prepared according to the present invention.

FIG. 1E

is a SEM taken at a magnification of 20,000× of microsphers containing itraconazole prepared according to the present invention.

FIG. 1F

is a SEM taken at a magnification of 20,000× of microsphers containing itraconazole prepared according to the present invention.

FIG. 1G

is a SEM taken at a magnification of 2,000× of microsphers containing itraconazole prepared according to the present invention, after being mechanically crused.

FIG. 1H

is a SEM taken at a magnification of 3,500× of microsphers containing itraconazole prepared according to the present invention, after being mechanically crused.

DETAILED DESCRIPTION OF THE INVENTION

It has now been discovered that water insoluble or partially soluble imidazole derivatives can be solubilized in volatile organic acids. The resultant solutions can be used to prepare imidazole containing microspheres which are suitable for oral administration to animals.

Imidazole Derivatives

The active agents of the present invention are imidazole derivatives having the formula:

wherein

R, R

1

and R

2

are independently hydrogen or lower alkyl;

R

3

is hydrogen, methyl or ethyl;

R

4

is hydrogen or methyl

Ar is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono (lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or halothienyl;

Ar

1

is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or cyanophenyl; and

n is 1 or 2.

A preferred imidazole derivative is itraconazole. Itraconazole is a synthetic triazole imidazole derivative 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers (

Physicians Desk Reference

48th Ed., pg. 1097, 1994).

Imidazole Derivative Solutions

The solutions prepared in accordance with the present invention allow for the solubilization of imidazole derivatives at concentrations suitable for processing into orally administrable forms having acceptable bioavailability.

In accordance with the present invention, imidazole derivatives are solubilized in volatile organic acid solvent(s). Preferred acid solvents for the imidazole derivatives are acetic acid and formic acid. Preferably, the solvent itself is an aqueous solution of the acid. Most preferably the volume:volume ratio of the acid to the total volume of the solvent is 3:7 or greater. It has been found that by using this solvent system up to a 50% solution of imidazole derivative can be prepared.

Dissolution is achieved by simple mixing, with heating if necessary. The more concentrated the acid in the solvent, the greater the amount of active agent that can be incorporated into the solution. If lower concentrations of acid are required for the end use of the solution, the active agent can first be dissolved in a more concentrated acid solution, and the resultant solution then slowly diluted further, preferably with water.

Preferably, the solution comprises from about 3 to about 40 percent by weight of solute and from about 60 to about 97 parts by weight of solvent based upon 100 parts by weight of solution.

The solvent itself, preferably comprises from about 30 to about 80 parts by volume of acid and from about 70 to about 20 parts by volume of water based upon 100 parts by volume of solvent. Most preferably, the solvent comprises from about 40 to about 50 parts by volume of acid and from about 60 to about 50 parts by volume of water based upon 100 parts by volume of solvent.

Microspheres

Microspheres are useful in the delivery of active agents because they protect an active agent cargo until it is delivered to a target. Microsphers are particularly useful in the oral delivery of biologically active agents such as for example, pharamaceutically active agents.

Microspheres containing an active agent can be generally of the matrix form or the capsule form. In a hollow matrix spheroid form, the center of the sphere is hollow and the cargo or active agent is distributed throughout a carrier matrix. In a solid matrix form, the carrier matrix forms a continuum in which the cargo is distributed. In the microcapsule form, the encapsulated material or cargo can be either in solution or a solid, with the carrier forming a shell around the cargo.

The methods of the present invention are cost-effective for preparing microspheres which contain imidazole derivatives, are simple to perform, and are amenable to industrial scale-up for commercial production.

Carriers

Carriers suitable for use in the present invention are microsphere forming carriers. These carriers include, without limitation, proteinoids; acylated amino acids, poly amino acids or salts thereof; sulfonated amino acids, poly amino acids or salts thereof; proteins or salts thereof, enteric coating materials; or any combination thereof.

Amino acids are the basic materials used to prepare many of the carriers useful in the present invention. Amino acids include any carboxylic acid having at least one free amino group and include naturally occurring and synthetic amino acids. The preferred amino acids for use in the present invention are ∝-amino acids and, most preferably, are naturally occurring ∝-amino acids. Many amino acids and amino acid esters are readily available from a number of commercial sources such as Aldrich Chemical Co. (Milwaukee, Wis., USA); Sigma Chemical Co. (St. Louis, Mo., USA); and Fluka Chemical Corp. (Ronkonkoma, N.Y., USA).

Representative, but not limiting, amino acids suitable for use in the present invention are generally of the formula

wherein:

R

5

is hydrogen, C

1

-C

4

alkyl, or C

2

-C

4

alkenyl;

R

6

is C

1

-C

24

alkyl, C

2

-C

24

alkenyl, C

3

-C

10

cycloalkyl, C

3

-C

10

cycloalkenyl, phenyl, naphthyl, (C

1

-C

10

alkyl) phenyl, (C

2

-C

10

alkenyl) phenyl, (C

1

-C

10

alkyl) naphthyl, (C

2

-C

10

alkenyl) naphthyl, phenyl (C

1

-C

10

alkyl), phenyl (C

2

-C

10

alkenyl), naphthyl (C

1

-C

10

alkyl), or naphthyl (C

2

-C

10

alkenyl);

R

6

being optionally substituted with C

1

-C

4

alkyl, C

2

-C

4

alkenyl, C

1

C

4

alkoxy, —OH, —SH, —CO

2

R

7

, C

3

-C

10

cycloalkyl, C

3

-C

10

cycloalkenyl, heterocycle having 3-10 ring atoms wherein the hetero atom is one or more of N, O, S, or any combination thereof, aryl, (C

1

-C

10

alk)aryl, ar(C

1

-C

10

alkyl) or any combination thereof;

R

6

being optionally interrupted by oxygen, nitrogen, sulfur, or any combination thereof; and

R

7

is hydrogen, C

1

-C

4

alkyl, or C

2

-C

4

alkenyl.

The preferred naturally occurring amino acids for use in the present invention as amino acids or components of a peptide are alanine, arginine, asparagine, aspartic acid, citrulline cysteine, cystine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, hydroxyproline, β-carboxyglutamic acid, γ-carboxyglutamic acid, phenylglycine, or O-phosphoserine. The most preferred amino acids are arginine, leucine, lysine, phenylalanine, tyrosine, tryptophan, valine, and phenylglycine.

The preferred non-naturally occurring amino acids for use in the present invention are β-alanine, α-amino butyric acid, γ-amino butyric acid, γ-(aminophenyl) butyric acid, α-amino isobutyric acid, ε-amino caproic acid, 7-amino heptanoic acid, β-aspartic acid, aminobenzoic acid, aminophenyl acetic acid, aminophenyl butyric acid, γ-glutamic acid, cysteine (ACM), ε-lysine, methionine sulfone, norleucine, norvaline, ornithine, d-ornithine, p-nitro-phenylalanine, hydroxy proline, 1,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, and thioproline.

Poly amino acids are either peptides or two or more amino acids linked by a bond formed by other groups which can be linked, e.g., an ester or an anhydride linkage. Special mention is made of non-naturally occurring poly amino acids and particularly non-naturally occurring hetero-poly amino acids, i.e. of mixed amino acids.

Peptides are two or more amino acids joined by a peptide bond. Peptides can vary in length from di-peptides with two amino acids to polypeptides with several hundred amino acids. See, Walker,

Chambers Biological Dictionary,

Cambridge, England: Chambers Cambridge, 1989, page 215. Special mention is made of non-naturally occurring peptides and particularly non-naturally occurring peptides of mixed amino acids. Special mention is also made of di-peptides tri-peptides, tetra-peptides, and penta-peptides, and particularly, the preferred peptides are di-peptides and tri-peptides. Peptides can be homo- or hetero- peptides and can include natural amino acids, synthetic amino acids, or any combination thereof.

Proteinoids

Proteinoids are artificial polymers of amino acids. Proteinoids preferably are prepared from mixtures of amino acids. Preferred proteinoids are condensation polymers, and most preferably, are thermal condensation polymers. These polymers may be directed or random polymers. Proteinoids can be linear, branched, or cyclical, and certain proteinoids can be units of other linear, branched, or cyclical proteinoids.

Special mention is made of diketopiperazines. Diketopiperazines are six member ring compounds. The ring includes two nitrogen atoms and is substituted at two carbons with two oxygen atoms. Preferably, the carbonyl groups are at the 2 and 5 ring positions. These rings can be optionally, and most often are, further substituted.

Diketopiperazine ring systems may be generated during thermal polymerization or condensation of amino acids or amino acid derivatives. (Gyore, J; Ecet M.

Proceedings Fourth ICTA

(

Thermal Analysis

), 1974, 2, 387-394 (1974)). These six membered ring systems were presumably generated by intra-molecular cyclization of the dimer prior to further chain growth or directly from a linear peptide (Reddy, A. V.,

Int. J. Peptide Protein Res.,

40, 472-476 (1992); Mazurov, A. A. et al.,

Int. J. Peptide Protein Res.,

42, 14-19 (1993)).

Diketopiperazines can also be formed by cyclodimerization of amino acid ester derivatives as described by Katchalski et al.,

J. Amer. Chem. Soc.,

68, 879-880 (1946), by cyclization of dipeptide ester derivatives, or by thermal dehydration of amino acid derivatives and high boiling solvents as described by Kopple et al.,

J. Org. Chem.,

33 (2), 862-864 (1968).

Diketopiperazines typically are formed from α-amino acids. Preferably, the α-amino acids of which the diketopiperazines are derived are glutamic acid, aspartic acid, tyrosine, phenylalanine, and optical isomers of any of the foregoing.

Modified Amino Acids and Poly Amino Acids

Modified amino acids, poly amino acids, or peptides are either acylated or sulfonated and include amino acid amides and sulfonamides.

Acylated Amino Acids and Poly Amino Acids

Although any acylated amino acids or poly amino acids are useful in the present invention, special mention is made of acylated amino acids having the formula

Ar

2

—Y—(R

8

)

n

—OH III

wherein Ar

2

is a substituted or unsubstituted phenyl or naphthyl;

R

8

has the formula

wherein:

R

9

is C

1

to C

24

alkyl, C

1

to C

24

alkenyl, phenyl, naphthyl, (C

1

to C

10

alkyl) phenyl, (C

1

to C

10

alkenyl) phenyl, (C

1

to C

10

alkyl) naphthyl, (C

1

to C

10

alkenyl) naphthyl, phenyl (C

1

to C

10

alkyl), phenyl (C

1

to C

10

alkenyl), naphthyl (C

1

to C

10

alkyl) and naphthyl (C

1

to C

10

alkenyl);

R

9

is optionally substituted with C

1

to C

4

alkyl, C

1

to C

4

alkenyl, C

1

to C

4

alkoxy, —OH, —SH and —CO

2

R

11

, cycloalkyl, cycloalkenyl, heterocyclic alkyl, alkaryl, heteroaryl, heteroalkaryl, or any combination thereof;

R

11

is hydrogen, C

1

to C

4

alkyl or C

1

to C

4

alkenyl;

R

9

is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof; and

R

10

is hydrogen, C

1

to C

4

alkyl or C

1

to C

4

alkenyl.

Special mention is also made of those having the formula

wherein:

R

12

is

(i) C

3

-C

10

cycloalkyl, optionally substituted with C

1

-C

7

alkyl, C

2

-C

7

alkenyl, C

1

-C

7

alkoxy, hydroxy, phenyl, phenoxy or —CO

2

R

15

, wherein R

15

is hydrogen, C

1

-C

4

alkyl, or C

2

-C

4

alkenyl; or

(ii) C

1

-C

6

. alkyl substituted with C

3

-C

10

cycloalkyl;

R

13

is hydrogen, C

1

-C

4

alkyl, or C

2

-C

4

alkenyl;

R

14

is C

1

-C

24

alkyl, C

2

-C

24

alkenyl, C

3

-C

10

cycloalkyl, C

3

-C

10

cycloalkenyl, phenyl, naphthyl, (C

1

-C

10

alkyl) phenyl, (C

2

-C

10

alkenyl) phenyl, (C

1

-C

10

alkyl) naphthyl, (C

2

-C

10

alkenyl) naphthyl, phenyl (C

1

-C

10

alkyl), phenyl (C

2

-C

10

alkenyl), naphthyl (C

1

-C

10

alkyl) or naphthyl (C

2

-C

10

alkenyl);

R

14

being optionally substituted with C

1

-C

4

alkyl, C

2

-C

4

alkenyl, C

1

-C

4

alkoxy, —OH, —SH, —CO

2

R

16

, C

3

-C

10

cycloalkyl, C

3

-C

10

cycloalkenyl, heterocycle having 3-10 ring atoms wherein the hetero atom is one or more of N, O, S or any combination thereof, aryl, (C

1

-C

10

alk)aryl, ar(C

1

-C

10

alkyl), or any combination thereof;

R

14

being optionally interrupted by oxygen, nitrogen, sulfur, or any combination thereof; and

R

16

is hydrogen, C

1

-C

4

alkyl, or C

2

-C

4

alkenyl.

Acylated amino acids may be prepared by reacting single amino acids, mixtures of two or more amino acids, or amino acid esters with an amine modifying agent which reacts with free amino moieties present in the amino acids to form amides.

Suitable, but non-limiting, examples of acylating agents useful in preparing acylated amino acids include acid chloride acylating agents having the formula

wherein:

R

17

an appropriate group for the modified amino acid being prepared, such as, but not limited to, alkyl, alkenyl, cycloalkyl, or aromatic, and particularly methyl, ethyl, cyclohexyl, cyclophenyl, phenyl, or benzyl, and X is a leaving group. Typical leaving groups include, but are not limited to, halogens such as chlorine, bromine and iodine.

Examples of the acylating agents include, but are not limited to, acyl halides including, but not limited to, acetyl chloride, propyl chloride, cyclohexanoyl chloride, cyclopentanoyl chloride, and cycloheptanoyl chloride, benzoyl chloride, hippuryl chloride and the like; and anhydrides, such as acetic anhydride, propyl anhydride, cyclohexanoic anhydride, benzoic anhydride, hippuric anhydride and the like. Preferred acylating agents include benzoyl chloride, hippuryl chloride, acetyl chloride, cyclohexanoyl chloride, cyclopentanoyl chloride, and cycloheptanoyl chloride.

The amine groups can also be modified by the reaction of a carboxylic acid with coupling agents such as the carbodiimide derivatives of amino acids, particularly hydrophilic amino acids such as phenylalanine, tryptophan, and tyrosine. Further examples include dicyclohexylcarbodiimide and the like.

If the amino acid is multifunctional, i.e. has more than one —OH, —NH

2

or —SH group, then it may optionally be acylated at one or more functional groups to form, for example, an ester, amide, or thioester linkage.

In acylated poly amino acids, one or more of the amino acids may be modified (acylated). Modified poly amino acids may include one or more acylated amino acid(s). Although linear modified poly amino acids will generally include only one acylated amino acid, other poly amino acid configurations can include more than one acylated amino acid. Poly amino acids can be polymerized with the acylated amino acid(s) or can be acylated after polymerization.

Sulfonated Amino Acids and Poly Amino Acids

Sulfonated amino acids and poly amino acids are modified by sulfonating at least one free amine group with a sulfonating agent which reacts with at least one of the free amine groups present.

Special mention is made of compounds of the formula

Ar

3

—Y—(R

18

)

n

—OH V

wherein

Ar

3

is a substituted or unsubstituted phenyl or naphthyl;

Y is —SO

2

—, R

18

has the formula

wherein:

R

19

is C

1

to C

24

alkyl, C

1

to C

24

alkenyl, phenyl, naphthyl, (C

1

to C

10

alkyl) phenyl, (C

1

to C

10

alkenyl) phenyl, (C

1

to C

10

alkyl) naphthyl, (C

1

to C

10

alkenyl) naphthyl, phenyl (C

1

to C

10

alkyl), phenyl (C

1

to C

10

alkenyl), naphthyl (C

1

to C

10

alkyl) and naphthyl (C

1

to C

10

alkenyl);

R

19

is optionally substituted with C

1

to C

4

alkyl, C

1

to C

4

alkenyl, C

1

to C

4

alkoxy, —OH, —SH and —CO

2

R

21

or any combination thereof;

R

21

is hydrogen, C

1

to C

4

alkyl or C

1

to C

4

alkenyl;

R

19

is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof; and

R

20

is hydrogen, C

1

to C

4

alkyl or C

1

to C

4

alkenyl.

Suitable, but non-limiting, examples of sulfonating agents useful in preparing sulfonated amino acids include sulfonating agents having the formula R

22

—SO

2

—X wherein R

22

is an appropriate group for the modified amino acid being prepared such as, but not limited to, alkyl, alkenyl, cycloalkyl, or aromatics and X is a leaving group as described above. One example of a sulfonating agent is benzene sulfonyl chloride.

Modified poly amino acids and peptides may include one or more sulfonated amino acid(s). Although linear modified poly amino acids and peptides used generally include only one sulfonated amino acid, other poly amino acid and peptide configurations can include more than one sulfonated amino acid. Poly amino acids and peptides can be polymerized with the sulfonated amino acid(s) or can be sulfonated after polymerization.

Proteins

Proteins are naturally occurring (i.e. not artificial) polymers of amino acids.

Enteric Coating Materials

Enteric coating materials known to those skilled in the art such as, for example, cellulose acetate trimellitate (CAT) and cellulose acetate phthalate (CAP), are suitable for use in the preservation as well.

Formation

These carriers, and particularly proteinoids, acylated amino acids or poly amino acids, sulfonated amino acids or poly amino acids, and proteins are often insoluble or relatively insoluble in neutral or mildly acidic solutions but are also soluble, as are the imidazole derivatives useful in the present invention, in aqueous acid solutions wherein the volume to volume ratio of acid to water is greater than about 3:7. Suitable aqueous acid solvents are as above, i.e. volatile organic acids, such as for example, aqueous acetic acid, aqueous formic acid, and the like. These acids will volatilize upon nebulization or can be diluted in the aqueous solution, thereby decreasing the concentration of the acid and reversing the solubility of the carrier even in the absence of a precipitator. For example, see currently filed U.S. Pat. application Ser. No. 08/475,882, filed on Jun. 7, 1995, now U.S. Pat. No. 5,667,806, entitled “SPRAY DRYING METHOD AND APPARATUS”.

Microsphere formation occurs when the concentration of the acid in the carrier/active agent solution is decreased. As this solution is nebulized, the acid evaporates, decreasing the concentration of the acid in solution to less than 30% by volume. The carrier, then, will self assemble to form microspheres containing any optional active agent. The cargo must be stable in the concentrated acid for the time and conditions necessary to carry out the operation. Alternately, the carrier solution can be diluted, such as with water, whereby the acid concentration is decreased and the carrier precipitates to form microspheres. Preferably, the microspheres are prepared by spray drying.

The microspheres can be pH adapted by using base or acid soluble coatings including, but not limited to, proteinoid coatings, enteric coatings, acylated amino acid coatings, and the like.

Any of the solutions above may optionally contain additives such as stabilizing additives. The presence of such additives promotes the stability and dispersability of the active agent in solution. The stabilizing additives may be employed at a concentration ranging between about 0.1 and 5% (w/v), preferably about 0.5% (w/v). Suitable, but non-limiting examples of stabilizing additives include buffer salts, gum acacia, gelatin, methyl cellulose, polyethylene glycol, and polylysine.

The amount of active agent that may be incorporated in the microsphere is dependent upon a number of factors which include the concentration of active agent in the solution as well as the affinity of the active agent for the carrier. The concentration of the active agent in the final formulation also will vary depending on the required amounts for any particular end use. When necessary, the exact concentration can be determined by, for example, reverse phase HPLC analysis.

The microspheres and, therefore, the solutions described above may also include one or more enzyme inhibitors. Such enzyme inhibitors include, but are not limited to, compounds such as actinonin or epiactinonin and derivatives thereof.

The microspheres are particularly useful for administering itraconazole derivatives to any animals, including but not limited to, birds and mammals, such as primates and particularly humans; and insects. These microsphere systems are particularly advantageous for delivering these active agents as the active agent would otherwise be destroyed or rendered less effective by conditions encountered before the microsphere reaches the active agent target zone (i.e., the area in which the active agent of the delivery composition are to be released) and within the body of the animal to which they are administered. Furthermore, these microspheres can deliver relatively high amounts of the imidazole derivative and retain a high bioavailability.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The following examples illustrate the present invention without limitation.

EXAMPLE 1

Solubilization of Itraconazole

Acetic acid solutions were prepared in water to 10%, 20%, 50% and 75% concentrations (expressed as volume glacial acetic acid/total volume of solution ×100). 100 mg itraconazole solute were then mixed independently with 1 ml of each solution and visually monitored for dissolution. If necessary, additional 1 ml aliquots of each acetic acid solution were added until the itraconazole solute was dissolved.

Results are illustrated in Table 1 below. The solubilized material did not precipitate readily.

TABLE 1

SOLUBILITY

Concentration

Amount of Solvent

of

1 ml

1 ml

2 ml

2 ml

3 ml

3 ml

4 ml

4 ml

Acid in Solvent

Cold

Hot

Cold

Hot

Cold

Hot

Cold

Hot

10% Acetic

Ins.

Ins.

Ins.

Ins.

Ins.

Ins.

—

Ins.

Acid v:v

20% Acetic

Ins.

Ins.

Ins.

Ins.

Ins.

Part

—

—

Acid v:v

Sol.

50% Acetic

Ins.

Ins.

Ins.

Sol.

Ins.

—

—

—

Acid v:v

75% Acetic

Sol.

—

—

—

—

—

—

—

Acid v:v

EXAMPLE 2

Solubilization of Itraconazole

100 mg of itraconazole solute were dissolved in 1 ml glacial acetic acid solvent and aqueous acetic acid solvent at various concentrations. Results are illustrated in Table 2 below.

TABLE 2

ITRACONAZOLE SOLUTE

% Acetic Acid (v:v)

Dissolved Itraconazole %

100

>33 (dissolves freely on addition)

75

>10 (dissolves freely on addition)

40

5 (diss. conc. acid, then dilute)

20

2.5 (diss. conc. acid, then dilute)

EXAMPLE 3

Preparation of Itraconazole-Containing Microspheres One-Solution Method

60 grams of itraconazole solute (Janssen Pharmaceutica) were added to 1.43 liters of glacial acetic acid solvent, and the mixture was stirred to dissolve the solute. 1.43 liters of water were then added using a pump at a flow rate of 25 ml/min. Slight clouding of the solution was observed, but cleared upon further stirring. 166 grams of proteinoid (Glu-Asp-Tyr-Phe-Orn) were added and dissolved with further stirring. The final solution was filtered through folded tissue paper.

Using peristaltic pumps, the solution was fed through a Virtis SD04 spray drying apparatus under the conditions of Table 3 below.

TABLE 3

SPRAY DRYING CONDITIONS

Solution flow rate

7-8 ml/min

Inlet temperature

175° C.

Outlet temperature

116° C.

Blower speed

full

Compressor pressure

full

Stable proteinoid microspheres containing itraconazole were formed. Analysis of typical microspheres using RP-HPLC demonstrated that they contained 14-21% itraconazole by weight.

Scanning electron microscopy in

FIGS. 1A-1H

illustrates that the microspheres were smooth and spherical and had diameters ranging from 0. 1μm to about 5μm. When mechanically crushed only the larger spheres shattered, while the smaller spheres remained intact. Crushing revealed a solid internal structure. See,

FIG. 1G and 1H

.

All patents, applications, publications, and test methods mentioned herein are hereby incorporated by reference in their entirety.

Many variations of the present invention will suggest themselves to those skilled in the art in light of the above-detailed description in which obvious variations are within the full intended scope of the appended claims.

Claims

1. A method for preparing imidazole derivative active agent containing microspheres, said method comprising(A) nebulizing a solution comprising (a) an imidazole active agent having the formula wherein R, R1, and R2 are independently hydrogen or lower alkyl; R3 is hydrogen, methyl or ethyl; R4 is hydrogen or methyl; Ar is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or halothienyl; Ar1 is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or cyanophenyl; and n is 1 or 2; (b) a microsphere forming carrier selected from the group consisting of (i) a proteinoid; (ii) an acylated amino acid or poly amino acid or a salt thereof; (iii) a sulfonated amino acid or poly amino acid or a salt thereof; (iv) a protein or a salt thereof; (v) an enteric coating material; and (vi) any combination thereof; and (c) an active agent and carrier solubilizing effective amount of a solvent comprising an aqueous solution of at least one volatile organic acid; wherein the volume:volume ratio of acid to water in said solvent is at least about 3:7; and (B) decreasing said ratio to less than about 3:7, to yield said microspheres.
2. A method as defined in claim 1, wherein said imidazole derivative active agent comprises itraconazole.
3. A method as defined in claim 1, wherein said aqueous solution comprises aqueous acetic acid.
4. A method as defined in claim 1, wherein said nebulizing is performed by spray drying.
5. A method as defined in claim 1 wherein said ratio is decreased by volatilizing at least a portion of said acid.
6. A method as defined in claim 1 wherein said ratio is decreased by diluting said acid.
7. A method for preparing imidazole derivative active agent containing microspheres, said method comprising(A) nebulizing (a) solution comprising (i) an imidazole active agent having the formula wherein R, R1, and R2 are independently hydrogen or lower alkyl; R3 is hydrogen, methyl or ethyl; R4 is hydrogen or methyl; Ar is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or halothienyl; Ar1 is phenyl, monohalophenyl, dihalophenyl, trihalophenyl, mono(lower alkyl)phenyl, di(lower alkyl)phenyl, lower alkoxyphenyl, or cyanophenyl; and n is 1 or 2; and (ii) an active agent solubilizing effective amount of a solvent comprising an aqueous solution of at least one volatile organic acid; wherein the volume:volume ratio of acid to water in said solvent is at least about 3:7; and (b) a solution of a microsphere forming carrier selected from the group consisting of (i) a proteinoid; (ii) an acylated amino acid or poly amino acid or a salt thereof; (iii) a sulfonated amino acid or poly amino acid or a salt thereof; (iv) a protein or a salt thereof; (v) an enteric coating material; and (vi) any combination thereof; and (B) decreasing said ratio to less than about 3:7, to yield said microspheres.

Parent Case Info

This is a divisional of U.S. application Ser. No. 08/967,486, filed Nov. 11, 1997, now U.S. Pat. No. 6,100,285, which is a divisional of U.S. application Ser. No. 08/475,887, filed Jun. 7, 1995, now U.S. Pat. No. 5,750,147. These prior applications are hereby incorporated herein by reference, in their entirety.

US Referenced Citations (156)

Number	Name	Date	Kind
2671451	Bolger	Mar 1954	A
2828206	Rosenberg	Mar 1958	A
2862918	Meyer et al.	Dec 1958	A
2868740	Luce	Jan 1959	A
RE24899	Green	Nov 1960	E
2971916	Schleicher et al.	Feb 1961	A
3016308	Macaulay	Jan 1962	A
3052655	Fox et al.	Sep 1962	A
3057344	Abella et al.	Oct 1962	A
3076790	Fox et al.	Feb 1963	A
3170802	Fukushima	Feb 1965	A
3190837	Brynko et al.	Jun 1965	A
3474777	Figge et al.	Oct 1969	A
3491093	Pachter et al.	Jan 1970	A
3565559	Sato	Feb 1971	A
3567650	Bakan	Mar 1971	A
3574832	Engel et al.	Apr 1971	A
3576758	Emrick	Apr 1971	A
3687926	Arima et al.	Aug 1972	A
3725113	Chang	Apr 1973	A
3748277	Wagner	Jul 1973	A
3794561	Matsukawa et al.	Feb 1974	A
3795739	Birkmayer et al.	Mar 1974	A
3816404	Kablaoui et al.	Jun 1974	A
3822348	Higashi et al.	Jul 1974	A
3849550	Teitelbaum	Nov 1974	A
3933873	Love et al.	Jan 1976	A
3937668	Zolle	Feb 1976	A
3939253	Bodor et al.	Feb 1976	A
3956172	Saeki et al.	May 1976	A
3962416	Katzen	Jun 1976	A
3976773	Curran	Aug 1976	A
4035507	Bodor et al.	Jul 1977	A
4048268	Ludwig	Sep 1977	A
4061466	Sjoholm et al.	Dec 1977	A
4117801	Dannelly et al.	Oct 1978	A
4147767	Yapel	Apr 1979	A
4183849	Hansen	Jan 1980	A
4199561	Roth et al.	Apr 1980	A
4217370	Rawlings et al.	Aug 1980	A
4238506	Stach et al.	Dec 1980	A
4239635	Rieder	Dec 1980	A
4239754	Sache et al.	Dec 1980	A
4272506	Schwarzberg	Jun 1981	A
4289759	Heavner et al.	Sep 1981	A
4345588	Widder et al.	Aug 1982	A
4348384	Horikoshi et al.	Sep 1982	A
4351337	Sidman	Sep 1982	A
4352883	Lim	Oct 1982	A
4357259	Senyei et al.	Nov 1982	A
4388304	Nyeki et al.	Jun 1983	A
4393192	Curatolo et al.	Jul 1983	A
4402856	Schnoring et al.	Sep 1983	A
4402968	Martin	Sep 1983	A
4405598	Brown	Sep 1983	A
4442090	Kakeya et al.	Apr 1984	A
4446138	Pack	May 1984	A
4450150	Sidman	May 1984	A
4457907	Porter	Jul 1984	A
4460563	Calanchi	Jul 1984	A
4462839	McGinley et al.	Jul 1984	A
4462991	Higuchi et al.	Jul 1984	A
4473620	Wu et al.	Sep 1984	A
4483807	Asano	Nov 1984	A
4492684	Goosen et al.	Jan 1985	A
4518433	McGinley et al.	May 1985	A
4590265	Bogan et al.	May 1986	A
4608278	Frank	Aug 1986	A
4613500	Suzuki et al.	Sep 1986	A
4647455	De Bold	Mar 1987	A
4666641	Fickat et al.	May 1987	A
4671954	Goldberg	Jun 1987	A
4673566	Goosen et al.	Jun 1987	A
4683092	Trang	Jul 1987	A
4690786	Ninomiya et al.	Sep 1987	A
4692284	Braden	Sep 1987	A
4692433	Hostetler et al.	Sep 1987	A
4703042	Bodor	Oct 1987	A
4708952	Salatinjants	Nov 1987	A
4745161	Saudek et al.	May 1988	A
4753804	Iaccheri et al.	Jun 1988	A
4757007	Satoh	Jul 1988	A
4757024	Roper	Jul 1988	A
4757066	Shiokari et al.	Jul 1988	A
4766012	Valenti	Aug 1988	A
4774320	Tagliabue et al.	Sep 1988	A
4789734	Pierschbacher	Dec 1988	A
4835312	Itoh et al.	May 1989	A
4837381	Steber et al.	Jun 1989	A
4844904	Hamaguchi et al.	Jul 1989	A
4865614	Ploog et al.	Sep 1989	A
4873087	Morishita et al.	Oct 1989	A
4886663	Houghten	Dec 1989	A
4895725	Kantor et al.	Jan 1990	A
4897444	Brynes et al.	Jan 1990	A
4900730	Miyauchi	Feb 1990	A
4908233	Takizawa et al.	Mar 1990	A
4919939	Baker	Apr 1990	A
4925673	Steiner	May 1990	A
4963364	Fox et al.	Oct 1990	A
4976968	Steiner	Dec 1990	A
4983402	Steiner	Jan 1991	A
4996292	Fox et al.	Feb 1991	A
5019400	Gombotz et al.	May 1991	A
5023374	Simon	Jun 1991	A
5039481	Pacifici et al.	Aug 1991	A
5041291	Bader et al.	Aug 1991	A
5055300	Gupta	Oct 1991	A
5066487	Morelle et al.	Nov 1991	A
5067961	Kelman et al.	Nov 1991	A
5069936	Yen	Dec 1991	A
5077278	Hafner et al.	Dec 1991	A
5100669	Hyon et al.	Mar 1992	A
5100918	Sunshine et al.	Mar 1992	A
5122367	Ron et al.	Jun 1992	A
5126147	Silvestri et al.	Jun 1992	A
5137892	Chu et al.	Aug 1992	A
5186947	Goettsche et al.	Feb 1993	A
5204099	Barbier et al.	Apr 1993	A
5206384	Shibahara et al.	Apr 1993	A
5216124	Hansen, Jr. et al.	Jun 1993	A
5244653	Berke et al.	Sep 1993	A
5250236	Gasco	Oct 1993	A
5271934	Goldberg et al.	Dec 1993	A
5271961	Mathiowitz et al.	Dec 1993	A
5278148	Branca et al.	Jan 1994	A
5310535	Kruper, Jr. et al.	May 1994	A
5328992	Peter et al.	Jul 1994	A
5352461	Feldstein et al.	Oct 1994	A
5384133	Boyes et al.	Jan 1995	A
5389377	Chagnon et al.	Feb 1995	A
5389379	Dirix et al.	Feb 1995	A
5401516	Milstein et al.	Mar 1995	A
5418010	Janda et al.	May 1995	A
5439686	Desai et al.	Aug 1995	A
5443841	Milstein et al.	Aug 1995	A
5447728	Milstein et al.	Sep 1995	A
5451410	Milstein et al.	Sep 1995	A
5474997	Gray et al.	Dec 1995	A
5530137	Owiti et al.	Jun 1996	A
5536813	Charpenel et al.	Jul 1996	A
5540939	Milstein et al.	Jul 1996	A
5541155	Leone-Bay et al.	Jul 1996	A
5578323	Milstein et al.	Nov 1996	A
5601846	Milstein et al.	Feb 1997	A
5629020	Leone-Bay et al.	May 1997	A
5643957	Leone-Bay et al.	Jul 1997	A
5650386	Leone-Bay et al.	Jul 1997	A
5665700	Cho et al.	Sep 1997	A
5667806	Kantor	Sep 1997	A
5693338	Milstein	Dec 1997	A
5709861	Santiago et al.	Jan 1998	A
5714167	Milstein et al.	Feb 1998	A
5750147	Kantor	May 1998	A
6051258	Kantor	Apr 2000	A
6100285	Kantor	Aug 2000	A

Foreign Referenced Citations (76)

Number	Date	Country
1077842	Aug 1976	CA
2 424 169	Dec 1974	DE
2 343 037	Mar 1975	DE
3 202 255	Oct 1982	DE
3 612 102.9	Oct 1986	DE
0 000 667	Feb 1979	EP
0 036 145	Sep 1981	EP
0 068 314	Jan 1983	EP
0 105 804	Apr 1984	EP
0 130 162	Jan 1985	EP
0 170 540	Feb 1986	EP
0 342 054	Nov 1989	EP
0 342 056	Nov 1989	EP
0 365 183	Apr 1990	EP
0 366 277	May 1990	EP
0 418 642	Mar 1991	EP
0 448 057	Sep 1991	EP
0 452 161	Oct 1991	EP
0 459 795	Dec 1991	EP
0 467 389	Jan 1992	EP
0 490 549	Jun 1992	EP
0 517 211	Sep 1992	EP
0 616 799	Sep 1994	EP
1 351 358	Mar 1964	FR
1 468 601	Feb 1967	FR
2 133 926	Dec 1972	FR
2 326 934	May 1977	FR
2 565 102	Dec 1985	FR
929401	Jun 1963	GB
1 075 952	Aug 1967	GB
1 236 885	Jun 1971	GB
1 567 763	May 1980	GB
2 095 994	Oct 1982	GB
712582	Dec 1987	IL
48-24246	Mar 1973	JP
56-68612	Jun 1981	JP
58-35111	Mar 1983	JP
06-107682	Apr 1994	JP
280825	Dec 1964	NL
280826	Dec 1964	NL
B-146698	Nov 1982	NO
WO 8500105	Jan 1985	WO
WO 8500110	Jan 1985	WO
WO 8704076	Jul 1987	WO
WO 8801213	Feb 1988	WO
WO 9219263	Dec 1992	WO
WO 9318754	Sep 1993	WO
WO 9325583	Dec 1993	WO
WO 9411015	May 1994	WO
WO 9414420	Jul 1994	WO
WO 9418950	Sep 1994	WO
WO 9418997	Sep 1994	WO
WO 9421234	Sep 1994	WO
WO 9423702	Oct 1994	WO
WO 9423767	Oct 1994	WO
WO 9424291	Oct 1994	WO
WO 9428878	Dec 1994	WO
WO 8500809	Feb 1995	WO
WO 9511690	May 1995	WO
WO 8502772	Jul 1995	WO
WO 9528838	Nov 1995	WO
WO 9528920	Nov 1995	WO
WO 9612473	May 1996	WO
WO 9612474	May 1996	WO
WO 9612475	May 1996	WO
WO 9621464	Jul 1996	WO
WO 9630036	Oct 1996	WO
WO 9633699	Oct 1996	WO
WO 9639835	Dec 1996	WO
WO 9640070	Dec 1996	WO
WO 9640076	Dec 1996	WO
WO 9710197	Mar 1997	WO
WO 9731938	Sep 1997	WO
WO 9736480	Oct 1997	WO
WO 9747270	Dec 1997	WO
WO 9747288	Dec 1997	WO

Non-Patent Literature Citations (151)

Entry
The Condensed Chemical Dictionary, 6th Edition, Edited by Rose et al., Reinhold Publ. Corp., New York (1961), pp. 6&7.*
Airaudo, C.B. et al. (1987) Journal of Food Science, vol. 52(6), pp. 1750-1752.
Andini, S. et al. (1975) Origins of Life, vol. 6, pp. 147-153.
Brooke, S. 1 et al. (1977) BioSystems, vol. 9, pp. 1-22.
Chen et al. (1975) “Evidence for Hemiacetal Formation”, Biochemistry, vol. 18, No. 5, pp. 921-925.
Davis et al. (1983) “Leucinal Inhibits . . . ”, Pharmacology Biochemistry Behavior, vol. 19, pp. 791-794.
Dose, K. (1974) Origins of Life, vol. 5, pp. 239-252.
Fasman et al. (1964) Biochemistry, vol. 3, No. 11, pp. 1665-1674.
Fox, S.W. et al. (1976) BioSystems, vol. 8, pp. 40-44.
Fox, S.W. et al., Molecular Evolution and the Origin of Life, Maxel Decker, New York (1977).
Fox, S.W. et al. (1968) Biochim. Biophys. Acta, vol. 160, pp. 246-249.
Fox, S.W. (1976) Origins of Life, vol. 7, pp. 49-68.
Fox, S.W. (1980) Naturwissenschaften, vol. 67, pp. 378-383.
Fox, S.W. et al. (1960) Archives of Biochemistry and Biophysics, vol. 86, pp. 281-285.
Fox, S.W. et al. (1974) Origins of Life, vol. 5, pp. 227-237.
Fox, S.W. (1984) Origins of Life, vol. 14, pp. 485-488.
Gol'dovskii, A.M. (1978) Zhurnal Evolyutsionnoi Biokhimii i Fiziologii, vol. 14(6), pp. 437-439.
Gurrieri, S. et al. (1973) Thermochimica Acta, vol. 7, pp. 231-239.
Harada, K. et al. (1979) BioSystems, vol. 11, pp. 47-53.
Harada et al., (1960) Archives of Biochemistry and Biophysics, vol. 86, pp. 274-280.
Hare (1970) Etude Cenetique De La Polycondensation Thermique D'χ-Amino Acids, vol. 45, pp. 330-339.
Heinrich, M.R. et al. (1969) Archives of Biochemistry and Biophysics, vol. 130, pp. 441-448.
Heinz, B. et al. (1981) BioSystems, vol. 14, pp. 33-40.
Hennon, G. et al. (1975) Biochimie, vol. 57, pp. 1395-1396.
Hsu, L.L. et al. (1976) BioSystems, vol. 8, pp. 89-101.
Hsu, L.L. et al. (1971) Currents in Modern Biology, vol. 4, pp. 12-25.
Ishima, Y. et al. (1981), BioSystems, vol. 14, pp. 243-251.
Jackson et al. (1991) “Pharmacological . . . ”, J. Pharm. & Exp. Thera., vol. 261, No. 1, pp. 546-552.
Jungck, J.R. et al. (1973) Naturwissenschaften, vol. 60, pp. 425-427.
Kokufuta, E. et al. (1984) BioSystems, vol. 16, pp. 175-181.
Krampitz, G. et al. (1967) Naturwissenschaften, pp. 516-517.
Krampitz, G. et al. (1968) Naturwissenschaften, pp. 345 and 346.
Krampitz, G. et al. (1966) Naturwissenschaften, pp. 7 and 8.
Lacey, Jr., J.C. et al. (1979) BioSystems, vol. 11, pp. 9-17.
Lacey, Jr., J.C. et al. (1979) BioSystems, vol. 11, pp. 1-7.
Martinez Luque-Romero, M. et al. (1986) BioSystems, vol. 19, pp. 267-272.
Masinovsky, Z. et al. (1989) BioSystemsvol. 22, pp. 305-310.
Matsuno, K. (1982) BioSystems, vol. 15, pp. 1-11.
Matsuno, K. (1984) BioSystems, vol. 17, pp. 11-14.
Matsuno, K. (1981) BioSystems, vol. 14, pp. 163-170.
McAlhaney, W.W. et al. (1976) BioSystems, vol. 8, pp. 45-50.
Melius, P. et al. (1987) BioSystems, vol. 20, pp. 213-217.
Melius, P. et al. (1975) Bioorganic Chemistry, vol. 4, pp. 385-391.
Melius, P. (1979) BioSystems, vol. 11, pp. 125-132.
Miquel, J. et al. (1971) Currents in Modern Biology, vol. 3, pp. 299-306.
Nakashima, T. et al. (1980) J. Mol. Evol., vol. 15, pp. 161-168.
Nakashima, T. et al. (1981) BioSystems, vol. 14, pp. 151-161.
Novak, V.J.A. (1984) Origins of Life, vol. 14, pp. 513-522.
Olafsson, P.G. et al. (1971) Polymer Letters, vol. 9, pp. 521-528.
Phillips, R.D. et al. (1974) Int. J. Peptide Protein Res., vol. 6, pp. 309-319.
Przybylski, A.T. et al. (1982) Die Naturwissenschaften, vol. 69, pp. 561-563.
Przybylski, A.T. et al. (1984) Applied Biochemistry and Biotechnology, vol. 10, pp. 301-307.
Przybylski, A.T. (1985) BioSystems, vol. 17, pp. 281-288.
Rohlfing, D.L. (1975) Origins of Life, vol. 6, pp. 203-209.
Rohlfing, D.L. (1970) Science, vol. 169, pp. 998-1000.
Rohlfing, D.L. (1967) Archives of Biochemistry and Biophysics, vol. 118, pp. 468-474.
Rohlfing, D.L. et al. Catalytic Activities of Thermal Polyanhydro-α-Amino Acids, pp. 373-418, 1969.
Rohlfing, D.L. et al. (1976) BioSystems, vol. 8, pp. 139-145.
Ryan, J.W. et al. (1973) BioSystems, vol. 5, pp. 115-118.
Saunders, M.A. et al. (1974) BioSystems, vol. 6, pp. 81-92.
Snyder, W.D. et al. (1975) BioSystems, vol. 7, pp. 222-229.
Sokol, P.E. (1974) Journal of the American Oil Chemists' Society, vol. 52, pp. 101-102.
Tschager et al. (1988) Milchwirtschaftliche Berichte, vol. 95, pp. 79-83.
Vaughan, G. et al. (1987) BioSystems, vol. 20, pp. 219-223.
Vol'kenshtein, M.V. (1989) Molekulyarnaya Biologiya, vol. 23 (1), pp. 23-37.
Waehneldt, T.V. et al. (1968) Biochim. Biophys. Acta, vol. 160, pp. 239-245.
Williams et al. (1991) J. Biol. Chem., vol. 266, No. 8, pp. 5182-5190.
Yuki, A. et al. (1969) Biochemical and Biophysical Research Communications, vol. 36(4), pp. 657-663.
Zulaski et al. (1983) “New Carboxyalkyl Inhibitors of Brain Enkenphalinase”, J. Med. Chem., 26, pp. 60-65.
(1985) Chemical Abstracts, vol. No. 105(1), Abstract No. 12027p.
(1985) Chemical Abstracts, vol. No. 102(6), Abstract No. 50870d.
Chemical Abstract, vol. 80(9) Abst. No. 52392a.
Bergeron, Raymond J., et al. (1994) “Macromolecular Self-Assembly of Diketopiperazine Tetrapeptides”, Journal of the American Chemical Society, vol. 116, pp. 8479-8484.
Bergeron, Raymond J., et al. (1993) “A Comparative Study of the Iron-Clearing Properties of Desferrithiocin Analogues With Desferrioxamine B in a Cebus Monkey Model”, Blood, vol. 81, No. 8, pp. 2166-2173.
Bergeron, Raymond J., (1992) “A Comparison of the Iron-Clearing Properties of 1,2-Dimethyl-3-Hydroxypyrid-4-One, 1,2-Diethyl-3-Hydroxypyrid-4-One, and Deferoxamine”, Blood, vol. 79, No. 7. pp. 1882-1890.
Bergeron, Raymond J., et al. (1991) “Evaluation of Desferrithiocin and Its Synthetic Analogs as Orally Effective Iron Chelators”, Journal of Medicinal Chemistry, vol. 34, No. 7, pp. 2072-2078.
Bergeron, Raymond et al., “A Comparative Evaluation of Iron Clearance Models”, Annals New York Academy of Sciences, pp. 278-393, Mar. 13-15, 1990.
Andriuoli, G., et al. (1990), Haemostasis 20 (suppl. 1):154-158.
Caramazza, I., et al. (1991), Thrombosis Research 62:785-789.
Guarini, S., et al. (1983), Experimentia 41:350-352.
Guarini, S., et al. (1985) Pharmacological Research Communications 17(8):685-697.
Dal Pozzo, A., et al. (1989), Thrombosis Research 56:119-124.
Gelb, R., et al (1983), Lite Sciences 33(1):83-85.
Watterberg et al. (1988), Pediatric Research, vol. 23, No. 4, part 2, p. 570A, col. 1, abstract No. 2209.
Bernstein (1985), Chest 87(1):68S-73S.
Damge et al. (1988), Diabetes 37:246-251.
Chemical Abstracts:83 184360k, (1975).
Amino, Y., et al., Chem. Pharm. Bull. 36(11):4426-4434 (1988).
Baughman, R.A. et al. Proc. of the 6th Inter'l Symp. on Recent Advs. in Drug Delivery Systems, Ctr. for Controlled Chem. Delivery, University of Utah, Feb. 22-25, 1993, Salt Lake City UT, pp. 179-180 “Method for Assessing The Stability of Proteinoid Microshperes”.
Haas, S. et al., “Assessment Of Stability Of Proteinoid Microspheres”, Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 20(1993), Controlled Release Society, Inc.
X. Ma, et al., Proceed Intern. Symp. Control. Rel. Bioact. Mater., 20 (1993), Controlled Release Society, Inc. “In Vitro Mechanistic Investigation of the Proteinoid Microsphere Oral Delivery System”.
Yen, H.-R H., et al., “Adsorption of Sulforhodamine 101 on Proteinoid Microspheres” Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 20 (1993), Controlled Release Society, Inc.
Presented at IBC Rational Drug Design Conference, San Diego, Calif.—Dec. 1994.
Leone-Bay et al., Presented at “Winter Conference on Medicinal and Biooganic Chemistry” Steamboat Springs, Colorado—Feb. 1995 “Microsphere Formation and Drug Delivery in a Series of Derivatized Amino Acids”.
Santiago et al., Pharm. Res. 11: 1994, p.S-298 “Oral Delivery of Heparin Microspheres made with Modified Amino Acids”.
Leone-Bay et al. Pharm. Res. 11: 1994, p.S-121 “Oral Delivery of Heparin using Acylated Amino Acids”.
Sarubbi et al., Pharm. Res. 11: 1994, p.S-299 “Oral Calcitonin Delivery using the PODDS Technology”.
Leipold et al., Pharm. Res. 11: 1994, p.S-298 “Oral Delivery of Interferon in Rats and Primates”.
Santiago et al., Pharm. Res. 11: 1994, p.S-298 “Evaluation in Rats of Vehicles for the Oral Delivery of Low Molecular Weight Heparin”.
X. Ma et al., PDD 7303 Pharmaceutical Research 9(10):S-244, 1992 (Oct. Supplement).
Milstein et al., Symposia Abstracts. AAPS Annual Meeting, San Antonia, TX, Nov. 15-19, 1993.
Santiago et al. “Initial Studes In The Assessment of Proteinoid Microsphere Activity” Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 20 (1993), Controlled Release Society, Inc.
Santiago et al. “Oral Immunization of Rats with Influenza Virus M Protein (M1) Microspheres” Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 19 (1992), Controlled Release Society, Inc., p. 116-117.
Santiago et al. “Proteinoid Microspheres For The Oral Delivery of Heparin” Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 19 (1992), Controlled Release Society, Inc. p 514-515.
Santiago et al. American Society for Microbiology 92nd General Meeting, Abstract of the General Meeting, p. 159, May 26-30, 1992.
Milstein et al. “Preparation And In Vitro Characterization Of Proteinoid Microspheres” Proceed Intern. Symp. Control. Rel. Bioact. Mater., 19 (1992), Controlled Release Society, Inc. p. 516-517.
Doris K. Chiapetta, Eastern Analytical Symposium, Nov. 17, 1992 “Solutions for Problems in Bioanalysis”.
Elizabeth A. Harris. M.S., Eastern Analytical Symposium, Nov. 17, 1992 “Solutions for Problems in Bioanalysis”.
AAPS 6th Ann. Meeting and Expo., “Proteinoids—A Novel Drug Delivery System” Nov. 19, 1992, p. 33.
Milstein et al., “Efficient Oral Delivery Of Monoclonal Antibodies By Proteinoid Encapsulation” The 1993 Miami Bio/Technology Winter Sympsoium—Advances in Gene Technology: Protein Engineering and Beyond, Jan. 17-22, 1993.
Xinghang Ma, et al. “Stability Study of Drug-loaded Proteinoid Microsphere Formulations during Freeze-drying” Journal of Drug Targeting, 1994, vol. 2, pp 9-21.
Baughman et al., “Screening Candidate Microsphere Formulations By Incutabing In Simulated Digestive Fluids” Proc. of the 6th Intern'l. Sympo. on Recent Advances in Drug Delivery Systems, Ctr. for Controlled Chem. Delivery, University of Utah, Feb. 22-25, 1993, pp. 181-182.
Robert O. Dillman, M.D., Annals of Internal Medicine 1989:111 pp. 592-600, “Monoclonal Antibodies for Treating Cancer”.
Brendan D. Curti, Critical Reviews in Oncology/Hematology, 1993: 14 pp. 29-39 “Physical barriers to drug delivery in tumors”.
V. Hird et al, Genes and Cancer, edited by Desmond Carney & Karol Sikora, pp. 183-189, Immunotherapy with Monoclonal Antibodies.
Michael E. Osband et al., Immunology Today, vol. 11, No. 6, 1990, pp. 193-195. “Problems in the investigational study and clinical use of cancer immunotherapy”.
William J. Harris, Tibtech Feb. 1993 vol. 11, pp. 42-44 “Therapeutic antibodies—the coming of age”.
Thomas A. Waldmann, Science, Jun. 21, 1991, 252:1657-1662, “Monoclonal Antibodies in Diagnosis and Therapy”.
Chemical Abstracts, 76(14):72994u, (1971).
Chemical Abstracts, 84(7):44660d, (1975).
Chemical Abstracts, 86(16):107529g, (1976).
Chemical Abstracts, 112(15):134663h, (1989).
Chemical Abstracts, 114(22):214519x, (1990).
J. Györe et al., Theraml Analysis, vol. 2—Proceeding Fourth ICTA Budapest 1974, p. 387-394.
Chemical Abstracts, 99(19) 158832b, (1982).
Derwent Abstracts, JP 67008622, (1967).
Journal of Medicinal Chemistry, vol. 38, No. 21, pp. 4257-4262, (1995), “Microsphere Formation in a Series of Derivatized α-Amino Acids: Properties, Molecular Modeling, and Oral Delivery of Salmon Calcitonin”.
Andrea Leone-Bay et al., Journal of Medicinal Chemistry, vol. 38, No. 21, pp. 4263-4269, (1995), “N-Acylated α-Amino Acids as Novel Oral Delivery Agents for Proteins”.
The Extra Phamacopoeia, Thirtieth Edition, pp. 325-326, (1993).
Stephen J. Douglas et al., Chemistry and Industry, vol. 22:748-751, 1985.
C.A. Finch, Chemistry and Industry, vol. 22:752-756, 1985.
John A. Butera et al., J. Med. Chem., vol. 34:3212-3228, 1990.
Madeline G. Cimini et al., Ann. Report in Med Chem., vol. 27:89-98., 1992.
Bernadette Earley et al., Brain Research,vol. 546:282-286, 1991.
John W. Ellingboe et al., J. Med. Chem., vol. 35:705-716, 1992.
William C. Lumma et al., J. Med Chem., vol. 30:758-763, 1987.
Joseph J. Lynch et al., J. of Pharm. and Exp. Therap., vol. 269:541-554, 1994.
Kiyoshi Matsuno et al., Brain Research, vol. 575:315-319, 1992.
Thomas K. Morgan et al., J. Med. Chem., vol. 33:1091-1097, 1990.
Hitoshi Oinuma et al., J. Med. Chem., vol. 33:903-905, 1990.
Tadimeti S. Rao et al., Molecular Pharmacology, vol. 37:978-982, 1990.
Asaji Kondo, Microcapsule Processing and Technology, pp. 154-165, 1979.
G. Pastores et al., J. Liquid Chromatography, 18(15):3049-3059, 1995.
D. Sinha et al.,J. Bio. Chem., 260(19):10714-10719, 1985.
E. Franssen et al., J. Med. Chem., 35:1246-1259, 1992.
Chemical Abstracts, 99(23):191473h, Dec. 05, 1983.
R. Langer, Science, 249:1528, Sep. 28, 1990.
M. Alonso et al., Vaccine, 12:299, 1994.
A. Leone-Bay et al., J. Med. Chem., 39:2571-2578, 1996.
R. Thompson, Biochemistry, 12:47-51, 1973.
S. Thompson, J. Med. Chem., abstract, 86:174780, 1986.

Method of solubilizing and encapsulating itraconazole

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US